Find out more about the link between alpha-blockers and Parkinson’s disease risk.
Could a prostate drug lower the risk of Parkinson’s disease?
Author: Johanna Stiefler JohnsonPublished: 11 February 2021
Prep: Cook: Serves:
Researchers in the US, Denmark and China have found that a type of medication used to treat enlarged prostate, known as alpha-blockers, is associated with a lower risk of Parkinson’s disease.
As part of the study, the research team analysed patient data from 150,000 men using medications like the alpha-blocker terazosin – which has previously been shown to slow Parkinson’s disease progression in animals – and compared their findings to data from 150,000 men using the alpha-blocker tamsulosin. They found that men taking terazosin were 12 to 37% less likely to develop Parkinson’s disease.
Jacob Simmering, corresponding author of the study, said: “Despite the relative differences in population and health care system structure, we found a similar protective effect in both [the US and Denmark].
“If these results are confirmed through further investigation, especially a randomised clinical trial, terazosin may provide neuroprotection and potentially prevent – and not just manage – Parkinson’s disease.”
For more information on neuroprotection and Parkinson’s disease, please visit the EPDA website.
Share this story
Antioxidants could reduce risk of Parkinson’s disease by 32%, study finds
Antioxidant vitamins, found in foods like almonds, avocados and broccoli, cREAD MORE
Ask the expert: Can environmental factors cause Parkinson’s?
Dr Ray Dorsey on the impact of pesticidesREAD MORE
Loneliness may increase severity of Parkinson’s disease symptoms
Researchers in the US have found that people with Parkinson’s disease whoREAD MORE